• We are scientists and clinical researchers determining how genome instability arises following DNA damage and during cellular aging.
  • We are scientists and clinical researchers determining how genome instability arises following DNA damage and during cellular aging.
  • We are scientists and clinical researchers determining how genome instability arises following DNA damage and during cellular aging.

Our Core Research Team

We are nine independent laboratories working together to research (i) mechanisms of DNA damage and repair, (ii) translational applications of genome instability to the clinic and (iii) the pathways underlying human cellular aging.

Dr. Nizar Bahlis

Dr. Nizar Bahlis

Synergistic PARP & proteasome inhibition as multiple myeloma therapy.

Short Bio Summary

Dr. Bahlis is a practising haematologist at the Tom Baker Cancer Centre and an associate professor at the
Arnie Charbonneau Cancer Institute. He obtained his MD from the French Faculty of Medicine
(FFM-Lebanon) in 1995 and completed his medicine and hematology /oncology training at the State
University of NY in Syracuse and the University of Miami. He also completed a post-doctoral research
fellowship in cancer research under the mentorship of Dr Lawrence Boise.

Research Interests

Multiple myeloma (MM) is a hematological malignancy where plasma cells become cancerous. Aiming to improve the outcomes of patients affected by this disease, we have established a Myeloma Genome Sequencing Unit with the goal to identify novel druggable genomic alterations and unmask the mechanisms of drug resistance.

We are also studying genomic instability in this disease, in particular the role of the proteasome-ubiquitin pathway in DNA damage repair. The human DNA damage response is reliant upon signalling using the small modifier protein called Ubiquitin (Ub). Since Ub is recycled by the proteasome, proteasome inhibitors (PI) have the effect of depleting free Ub pools such that the DNA damage-induced Ub-mediated signalling fails. We have found that MM displays a particular sensitivity to PI in combination
with PARP inhibitors, and we are examining the molecular mechanisms underlying this effect.

Laboratory Members

Senior Research Associate:
Paola Neri
Lab Manager:
Annie Fong
Post Doctoral Fellow:
Ranjan Maity
Post Doctoral Fellow:
Jiri Slaiby

Productivity & Funding

Publications

pubmed

Grant Logos

irsc-cihrmmrftetry-fax-research-institute
flowerleukemia_and_lymphoma_society